新股消息 | 岸迈生物拟港股上市 中国证监会要求补充说明本次发行上市前后是否持续符合外商投资准入政策要求等

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional documentation from 12 companies, including Chaimai Biotech, regarding compliance with foreign investment policies prior to their public listing [1][2]. Group 1: Regulatory Requirements - Chaimai Biotech is required to clarify the legality of its domestic operational entity's past equity changes and compliance with foreign exchange registration and investment regulations [2]. - The CSRC has asked for a detailed explanation of the establishment and equity changes of the largest shareholder, Sanaron Inc., and its relationship with the actual controller and trust beneficiaries [2]. - The company must provide information on the natural person shareholders of Everlasting Wisdom Holdings Limited, which holds 5.37% of its shares, and explain the reasons and fairness of their investment [2]. Group 2: Business Overview - Chaimai Biotech is a clinical-stage biotechnology company focused on developing T-cell engagers for treating various cancers and autoimmune diseases [3][4]. - The company's oncology pipeline includes three clinical-stage candidates: EMB-01 targeting EGFR/cMET for colorectal cancer, EMB-06 targeting BCMA/CD3 for multiple myeloma, and EMB-07 targeting ROR1/CD3 for lymphoma and solid tumors [4]. - Additionally, Chaimai Biotech has three preclinical candidates in its pipeline, along with an immunology candidate, EMB-06, which is also in clinical stages [4].